Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 2/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.44 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.44 |
| ▸ | GRIK4 | Q16099 | 2/20 | 0.44 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.44 |
| ▸ | FBP1 | P09467 | 4/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.42 |
| ▸ | DNA2 | P51530 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL261338 | 0.82 | ALDH1A1 (0.44) | APEX1FBP1ADORA3DNA2CASP6 | |
| SCHEMBL4314490 | 0.78 | GRIK1 (0.44) | APEX1GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL4628780 | 0.77 | APEX1 (0.47) | APEX1GLAKDM4E | |
| SCHEMBL260928 | 0.75 | APEX1 (0.57) | APEX1GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL260929 | 0.75 | APEX1 (0.57) | APEX1GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL4660564 | 0.72 | APEX1 (0.45) | APEX1GLAKDM4E | |
| SCHEMBL261055 | 0.71 | FBP1 (0.41) | APEX1FBP1ADORA3DNA2CASP6 | |
| SCHEMBL261054 | 0.71 | FBP1 (0.41) | APEX1FBP1ADORA3DNA2CASP6 | |
| SCHEMBL3518684 | 0.71 | GRIK1 (0.46) | APEX1GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL2979855 | 0.70 | CCR2 (0.52) | GLAKDM4ECCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951042-B1 | SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1951051-B1 | SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-03 | — | — | EP | disclosed |
| US-8163752-B2 | Tricyclic anilide heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8133891-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1794146-B1 | TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-08-03 | — | — | EP | disclosed |
| US-7968540-B2 | Spirohydantoin tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7947677-B2 | Spirolactam tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7750010-B2 | Tricyclic anilide spirohydantion CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-03 | — | — | US | disclosed |
| WO-2008153852-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080214511-A1 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists | MERCK & CO., INC. (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1951051-A2 | SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1951042-A2 | SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1793827-A2 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1794146-A2 | TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007061694-A2 | SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061692-A2 | SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006031676-A2 | TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006031491-A2 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214511-A1 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | APEX1 4754/4885GRIK1 657/4885GRIA1 567/4885 |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | APEX1 4754/4885GRIK1 657/4885GRIA1 567/4885 |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, BDKRB2 | APEX1 4181/4885GRIK1 365/4885GRIA1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.